Research programme: antibacterials - Enanta
Alternative Names: 6,11 Carbon-bridged ketolides - Enanta; Bicyclolides - Enanta; Bridged bicyclic ketolides - Enanta; Bridged bicyclic macrolides - Enanta; EP-013159; EP-013529-07; EP-014413; EP-014831; EP-014887; EP-014940; EP-014944; EP-015072; EP-015369; EP-13043; EP-13118; EP-13159; EP-13417; EP-13543; EP-14389; EP-14401; EP-14413; EP-14922; Oxime bicyclolide derivatives - EnantaLatest Information Update: 04 Nov 2017
At a glance
- Originator Enanta Pharmaceuticals
- Class Ketolides; Macrolides; Small molecules
- Mechanism of Action Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Streptococcal infections; Vancomycin-resistant enterococcal infections
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (IV)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (IV)